Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder (AUTMER)

February 23, 2024 updated by: Assistance Publique - Hôpitaux de Paris

Evaluation of a Therapeutic Education Program for Pregnant Women With a First Child Diagnosed With an Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder (ASD) is a heterogeneous set of severe developmental abnormalities of the nervous system characterized by deficits affecting social interactions and verbal and non-verbal communication, as well as the presence of restricted interests, repetitive behaviors, and atypical sensory manifestations . ASD affects approximately 1% of the general population (Elsabbagh et al., 2012). Studies of siblings of individuals with ASD show that ASD is present in 7-20% of the offspring in families where a child has had a diagnosis of ASD and this prevalence increases if there are two diagnosed children.

Several studies show the benefits of interventions targeting parents' interaction strategies in the early phases of development of infants at high risk for ASDs, in reducing the risk itself or its severity. Very early intervention, due to the presence of significant brain plasticity at these stages, may be particularly effective in changing these emerging trajectories, from a "preventive intervention" perspective that would aim to mitigate developmental risk and alter prodromal symptom trajectories, rather than eliminate a condition.

Our hypothesis is that the implementation of a specific therapeutic education program during a new pregnancy in the mother of a child with a diagnosis of ASD (MER Program) could improve the mother's well-being, increase parenting communication skills, and thereby improve interaction with the newborn at high risk for ASD. If the infant is affected, it may also reduce the symptoms of the disorder. Indirectly, it could also improve the well-being of the other parent involved in the interaction.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Randomized controlled trial with deferred start, French multicenter stepped-wedge type.

The start date of the intervention in each center will be done by randomization, defining 2 periods: a control period located before the start of the intervention, and an experimental period located after the start of the intervention.

This design allows the principal investigating team to train the centers associated in turn with the intervention, and to have a control group with structured follow-up but without intervention.

All subjects will be included before 26 ADT and assigned to the control or experimental group, depending on the time of inclusion and the randomization of the center to which they belong.

The follow-up will be conducted in 2 phases: 1. during pregnancy and 2. After the birth of the child.

Subjects included were pregnant women who already had a child with an ASD diagnosis, the second parent if present, and the newborn at risk for an ASD diagnosis.

The primary objective of this study is to evaluate the effect of an innovative therapeutic education program (the MER program) versus control in pregnant women with a first child followed for ASD on the quality of interaction strategies of the mother-infant dyad at 10 months postpartum.

The primary endpoint was the caregiver non-directiveness subscore of the Manchester Assessment of Caregiver-infant Interaction (MACI) scale at 10 months postpartum. This subscore is both the most sensitive to intervention and predictive of ASD diagnosis.

The first secondary objective is the evaluation of the effect of the MER versus control program on:

  • maternal pregnancy-related anxiety (PRAQ-R2 score) ;
  • Anxious and depressive symptomatology and quality of life (WhoQoL-Bref score) in the mother and the second parent during pregnancy (EPDS score) and up to 20 months of age of the newborn (HAM-Anxiety and HAM-Depression scores);
  • perceived stress related to pregnancy (ALES score)
  • mother-infant interaction at 10 and 20 months (MACI score and subscore);
  • autistic signs in at-risk infants at 20 months (ADOS Toddler score);

The second secondary objective was to study variables that could impact the effect of the intervention, including

  • adherence: compliance with sessions, satisfaction of participants (PEI-Parent score) ;
  • other variables that could modulate the effect of the intervention: sociodemographic variables (socioeconomic level, family configuration, number of children); clinical profile of the mother (intellectual efficiency (Raven's PM score), psychiatric comorbidities (DIGS, SRS score)); clinical profile of the child already diagnosed (ADI-R and ADOS score; developmental level); clinical profile of the infant at risk (gestational age, MSEL, IBQ-R and ECBQ scores).

The third secondary objective was to describe the barriers and levers to the implementation of the intervention.

Characteristics related to the implementation of the intervention (recruitment, uptake, fidelity, and implementation) will be collected, as well as the profile of mothers who did not participate in the project.

Study Type

Interventional

Enrollment (Estimated)

132

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Paris, France, 75019
        • Hôpital Robert Debré
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Mothers of children with a diagnosis of ASD, in pregnancy (before the 26th week of amenorrhea);
  • The diagnosis of ASD of the older child has been made, according to the DSM IV-TR or DSM 5 criteria, formalized by a diagnostic evaluation including: the Autism Diagnostic Observation Schedule ADOS, the Autism Diagnostic Interview - Revised version (ADI-R) accompanied by a cognitive evaluation of the child (Wechsler/Mullen Scales of Early Learning/Raven's Progressive Matrices);
  • Informed consent from mother and sec

Exclusion Criteria:

  • Presence of a clearly identified and unstabilized severe psychiatric disorder in the mother (confirmed by medical interview and DIGS questionnaire conducted at the time of the inclusion visit) and/or intellectual disability;
  • Engagement in another form of individual therapeutic intervention.
  • Refusal of either parent (for child assessment, primary criterion)
  • Parents not proficient in French language
  • Persons (mother or second parent) under legal protection, guardianship or trusteeship, persons deprived of liberty, under court protection, under psychiatric care, under constraint, admitted to a health or social institution for purposes other than research
  • Persons with cognitive disorders or intellectual disabilities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control group
Pregnant women followed by the center in the period before the intervention is implemented (the start of which is determined by randomization)
Experimental: experimental group
Pregnant women followed by the center during the period after the intervention is implemented (the start of which is determined by randomization)

The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).

It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Manchester Assessment of Caregiver-infant Interaction (MACI) "caregiver non-directiveness" subscore
Time Frame: 5 months after delivery

mother-baby interaction in the experimental group versus the control group at 5 months postpartum.

This subscore is the most sensitive to intervention and predictive of ASD diagnosis.

5 months after delivery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
Time Frame: between 11 weeks and 26 weeks of gestation
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
between 11 weeks and 26 weeks of gestation
Pregnancy-Related Anxiety Questionnaire-Revised2 (PRAQ-R2) subscore
Time Frame: at 3 months after intervention
To evaluate the effect of the MER program on maternal anxiety related to pregnancy
at 3 months after intervention
Appraisal of Life Events Scale (ALES)
Time Frame: between 11 weeks and 26 weeks of gestation
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale)
between 11 weeks and 26 weeks of gestation
Appraisal of Life Events Scale (ALES)
Time Frame: at 3 months after intervention
Perceived pregnancy-related stress in the mother.scale with a list of adjectives, rated on a five-point Likert scale
at 3 months after intervention
Edimburgh Postnatal Depression Scale (EPDS)
Time Frame: 10 months after birth
used to assess the risk of postnatal depression and is useful for identifying the presence of anxiety symptoms.The threshold retained for the French validation is 10.5, above which a depression is possible and below which the risk is very low.
10 months after birth
quality of life score-Bref (WhoQol-Bref)
Time Frame: 10 months after birth
WHOQOL-BREF includes 26 items that measure the following broad domains: physical health, psychological health, social relationships and environment.
10 months after birth
parental anxiety score (HAM)
Time Frame: 10 months after birth
hetero-questionnaire with 14 items, measuring both the psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) expression of anxiety. Each item is rated on a Likert scale from 0 to 4 (total range 0-56, where <17= mild anxiety; 18-24= mild to moderate; 25-30 moderate to severe)
10 months after birth
mother's intelligence quotient
Time Frame: between 11 weeks and 26 weeks of gestation
measured by Raven's Progressive Matrices
between 11 weeks and 26 weeks of gestation
Social Responsiveness Scale (SRS)
Time Frame: between 11 weeks and 26 weeks of gestation
to refine the evaluation of social difficulties in a dimensional way
between 11 weeks and 26 weeks of gestation
Wechsler Mullen scale
Time Frame: between 11 weeks and 26 weeks of gestation
developmental level of the ASD child
between 11 weeks and 26 weeks of gestation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anita Beggiato, PHD, APHP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

October 11, 2021

First Submitted That Met QC Criteria

October 22, 2021

First Posted (Actual)

November 2, 2021

Study Record Updates

Last Update Posted (Estimated)

February 26, 2024

Last Update Submitted That Met QC Criteria

February 23, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Child Psychiatry

Clinical Trials on The M.E.R. program

Subscribe